Do you have a dispute with a business?
Make it public
KUUR THERAPEUTICS LIMITED
C/O BDO LLP 5 TEMPLE SQUARE, TEMPLE STREET, LIVERPOOL, L2 5RHPrevious name: CELL MEDICA LIMITED (changed on 13-Feb-2020)
Previous name: IMMUNOCODE LIMITED (changed on 18-Nov-2005)
Company Number: 05620555
Incorporation date: 11-Nov-2005
Status: Liquidation
Entity type: Private Limited Company
SIC codes:
21200 Manufacture of pharmaceutical preparations
72110 Research and experimental development on biotechnology
86900 Other human health activities
SUMMARY
This company is 18.4 years old and is currently liquidation. It is controlled by multiple entities. The company has positive equity (net assets) of GBP 19 thousand which has decreased from the previous year's figure of GBP 41.2 million. The latest reported revenue figure is GBP 24 thousand which is similar to the previous year's figure of GBP 24 thousand. Retained earnings is negative (GBP -134.4 million), which means the company has aggregate losses since it's inception or it has paid more dividends than it can afford; given the company's age, this is a sign of serious financial problems. The company has 1 active officers (directors or partners) who are or were officers of 1 other company. The company has no public disputes filed on the Business Disputes Register. There are no court cases involving the company that we are aware of.FINANCIALS (BETA)
Next accounts due: 25-Sep-2021Accounts Filed: GROUP (31-Dec-2018)
P&L Financials:
Year end | Currency | Revenue | Operating profit | Interest Received | Interest Paid | Tax | Net Profit GBP |
---|---|---|---|---|---|---|---|
31-Dec-2018 | GBP | 24,000 | -55,350,000 | 7,255,000 | 3,697,000 | 4,711,000 | -47,081,000 |
31-Dec-2017 | GBP | 24,000 | -25,710,000 | 1,101,000 | 11,680,000 | 6,385,000 | -29,904,000 |
31-Dec-2016 | GBP | 106,000 | -20,575,000 | 38,000 | 2,637,000 | 1,006,000 | -22,168,000 |
Balance Sheet Financials:
Year end | Currency | Cash | Current Assets | Current Liabilities | Debt | Share Capital | Premium Reserve | Retained Earnings | Net Assets |
---|---|---|---|---|---|---|---|---|---|
31-Dec-2018 | GBP | 14,000 | 19,000 | 7,000 | -134,432,000 | 19,000 | |||
31-Dec-2017 | GBP | 28,254,000 | 34,630,000 | 3,240,000 | 2,023,000 | 124,033,000 | 41,248,000 | ||
31-Dec-2016 | GBP | 8,189,000 | 11,271,000 | 1,393,000 | 79,770,000 | 25,691,000 |
VALUATION EVENTS (BETA)
Year end | Currency | % Equity | Sum raised | Pre-Money Valuation* | Post-Money Valuation* | Enterprise Value** |
---|---|---|---|---|---|---|
31-Dec-2018 | GBP | -10,547.37% | -126,030,000 | 127,224,895 | 1,194,895 | 50,075,895 |
31-Dec-2017 | GBP | 31.14% | 44,893,000 | 99,263,411 | 144,156,411 | 103,488,411 |
** Estimated based on average Cash and Debt levels during period
DISPUTES
No disputes filed on www.disputesregister.orgCOMPANY SECRETARY
Status | Name | Appointed on | Resigned on | Occupation | Nationality | All apointments (active/resigned) |
---|---|---|---|---|---|---|
Resigned | BROUGHTON SECRETARIES LIMITED | 06 Mar 2020 | 30 May 2022 | 234 - 409 | ||
Resigned | Mirza Zafar Iskander QADIR | 08 Dec 2016 | 31 Oct 2019 | 0 - 1 | ||
Resigned | Jeff HAMMEL | 04 Dec 2013 | 15 Nov 2016 | 0 - 1 | ||
Resigned | Tina Lesley CROMBIE | 05 Nov 2009 | 04 Dec 2013 | 0 - 1 | ||
Resigned | Sarah Britton HAVENS | 11 Nov 2005 | 05 Dec 2009 | 0 - 3 |
DIRECTORS
Status | Name | Appointed on | Resigned on | Occupation | Nationality | All appointments (active/resigned) |
Dissolved companies (rate) |
---|---|---|---|---|---|---|---|
Active | Daniel LANG | 04 May 2021 | Biotech Executive | American | 1 - 0 | 1 (100.0%) | |
Resigned | Kevin Sean BOYLE SR | 31 Jan 2020 | 04 May 2021 | Ceo | American | 0 - 1 | 1 (100.0%) |
Resigned | Christopher John NOWERS | 06 Aug 2018 | 31 Jan 2020 | Company Director | British | 0 - 3 | 2 (66.7%) |
Resigned | Julia Paige GREGORY | 27 Jun 2018 | 22 Jun 2020 | Company Director | American | 1 - 3 | 1 (25.0%) |
Resigned | IP2IPO SERVICES LIMITED | 28 Mar 2018 | 22 Jun 2020 | 69 - 233 | 94 (31.1%) | ||
Resigned | Nigel Aaron PITCHFORD | 06 Dec 2017 | 28 Mar 2018 | Chief Investment Officer | British | 0 - 1 | 1 (100.0%) |
Resigned | Annalisa Lisa Mary JENKINS | 06 Dec 2017 | 22 Jun 2020 | Ceo | British | 1 - 4 | 1 (20.0%) |
Resigned | Allan Patrick MARCHINGTON | 15 Mar 2017 | 31 Jan 2020 | Investor | British | 4 - 11 | 6 (40.0%) |
Resigned | Andrea PONTI | 01 Aug 2014 | 28 Mar 2018 | Company Director | Italian And American | 0 - 1 | 1 (100.0%) |
Resigned | Thomas, Dr HECHT | 01 Oct 2010 | 22 Jun 2020 | Biotechnology Consultant | German | 0 - 1 | 1 (100.0%) |
Resigned | Nigel Robert, Dr BURNS | 02 Jan 2008 | 30 Apr 2019 | Independent Consultant | British | 2 - 9 | 8 (72.7%) |
Resigned | Maina BHAMAN | 19 Feb 2007 | 06 Dec 2017 | Investment Manager | British | 0 - 1 | 1 (100.0%) |
Resigned | SWIFT INCORPORATIONS LIMITED | 11 Nov 2005 | 11 Nov 2005 | 3 - 80228 | 34097 (42.5%) | ||
Resigned | Gregg Stephen SANDO | 11 Nov 2005 | 01 Aug 2018 | Chief Executive Officer | British | 2 - 4 | 1 (16.7%) |
Average tenure of active directors: 2.9 years
Average tenure of resigned directors: 4.7 years
Average active director Dissolution Rate: 100.0%
DIRECTOR APPOINTMENTS IN OTHER COMPANIES
Name
|
||
---|---|---|
KUUR THERAPEUTICS LIMITED (05620555) - Liquidation | ✔ |
SHAREHOLDERS (BETA)
Shareholder name | Share class | Shares at confirmation date | ||||
---|---|---|---|---|---|---|
2020-09-23 | 2020-06-02 | 2019-11-11 | 2018-11-11 | 2017-11-11 | ||
KUUR THERAPEUTICS, INC. | ORDINARY | 40,005,335 100% | 0 0% | 0 0% | 0 0% | 0 0% |
BAYLOR COLLEGE OF MEDICINE | C PREFERENCE | 0 0% | 20,231,608 50.6% | 0 0% | 0 0% | 0 0% |
NORTRUST NOMINEES LIMITED A/C WIZ01 | C PREFERENCE | 0 0% | 2,843,823 7.11% | 2,843,823 14.1% | 2,843,823 14.1% | 1,231,546 7.36% |
THE BANK OF NEW YORK (NOMINEES) LIMITED | B PREFERENCE | 0 0% | 2,797,203 6.99% | 2,797,203 13.8% | 2,797,203 13.8% | 2,797,203 16.7% |
TOUCHSTONE INNOVATIONS BUSINESSES LLP | B PREFERENCE | 0 0% | 2,097,902 5.24% | 2,097,902 10.4% | 2,097,902 10.4% | 2,097,902 12.5% |
NORTRUST NOMINEES LIMITED A/C WIX01 | B PREFERENCE | 0 0% | 2,097,902 5.24% | 2,097,902 10.4% | 2,097,902 10.4% | 2,097,902 12.5% |
THE BANK OF NEW YORK (NOMINEES) LIMITED UKREITS | C PREFERENCE | 0 0% | 1,958,042 4.89% | 1,958,042 9.68% | 1,958,042 9.68% | 870,241 5.20% |
THE CANCER PREVENTION AND RESEARCH INSTITUTE OF TEXAS | A PREFERENCE | 0 0% | 1,822,437 4.56% | 1,822,437 9.01% | 1,822,437 9.01% | 1,822,437 10.9% |
TOUCHSTONE INNOVATIONS BUSINESSES LLP | C PREFERENCE | 0 0% | 1,433,567 3.58% | 1,433,567 7.09% | 1,433,567 7.09% | 637,141 3.81% |
GREGG SANDO | ORDINARY | 0 0% | 1,057,743 2.64% | 1,057,743 5.23% | 1,057,743 5.23% | 1,057,743 6.32% |
TOUCHSTONE INNOVATIONS BUSINESSES LLP | ORDINARY | 0 0% | 844,762 2.11% | 844,762 4.18% | 844,762 4.18% | 844,762 5.05% |
THE BANK OF NEW YORK (NOMINEES) LIMITED UKREITS | A PREFERENCE | 0 0% | 727,272 1.82% | 727,272 3.60% | 727,272 3.60% | 727,272 4.35% |
TOUCHSTONE INNOVATIONS BUSINESSES LLP | A PREFERENCE | 0 0% | 603,353 1.51% | 603,353 2.98% | 603,353 2.98% | 603,353 3.61% |
THE WELLCOME TRUST LIMITED | A PREFERENCE | 0 0% | 464,395 1.16% | 464,395 2.30% | 464,395 2.30% | 464,395 2.78% |
NOVO A/S | ORDINARY | 0 0% | 202,584 0.506% | 202,584 1.00% | 202,584 1.00% | 202,584 1.21% |
SV LIFE SCIENCES FUND IV, L.P. | ORDINARY | 0 0% | 152,036 0.380% | 152,036 0.752% | 152,036 0.752% | 152,036 0.909% |
HBM HEALTHCARE INVESTMENTS | ORDINARY | 0 0% | 100,769 0.252% | 100,769 0.498% | 100,769 0.498% | 100,769 0.602% |
GREGG SANDO | A PREFERENCE | 0 0% | 69,510 0.174% | 69,510 0.344% | 69,510 0.344% | 69,510 0.416% |
STATE STREET NOMINEES LIMITED A/C 34ZG | C PREFERENCE | 0 0% | 58,275 0.146% | 58,275 0.288% | 58,275 0.288% | 58,275 0.348% |
VENTURE INCUBATOR AG | ORDINARY | 0 0% | 54,965 0.137% | 54,965 0.272% | 54,965 0.272% | 54,965 0.329% |
BIOMEDINVEST1ILTD | ORDINARY | 0 0% | 43,638 0.109% | 43,638 0.216% | 43,638 0.216% | 0 0% |
HBM BIOCAPITAL INVEST LTD | ORDINARY | 0 0% | 34,452 0.086% | 34,452 0.170% | 34,452 0.170% | 34,452 0.206% |
CHARLES PUSEY | ORDINARY | 0 0% | 30,699 0.077% | 30,699 0.152% | 30,699 0.152% | 30,699 0.184% |
CLARUS LIFESCIENCES | | ORDINARY | 0 0% | 27,995 0.070% | 27,995 0.138% | 27,995 0.138% | 27,995 0.167% |
PAUL MOSS | ORDINARY | 0 0% | 25,699 0.064% | 25,699 0.127% | 25,699 0.127% | 25,699 0.154% |
HANS STAUSS | ORDINARY | 0 0% | 25,699 0.064% | 25,699 0.127% | 25,699 0.127% | 25,699 0.154% |
GAVIN SCREATON | ORDINARY | 0 0% | 25,699 0.064% | 25,699 0.127% | 25,699 0.127% | 25,699 0.154% |
STEPHEN MACKINNON | ORDINARY | 0 0% | 25,699 0.064% | 25,699 0.127% | 25,699 0.127% | 25,699 0.154% |
INTERNATIONAL BIOTECHNOLOGY TRUST | ORDINARY | 0 0% | 18,995 0.047% | 18,995 0.094% | 18,995 0.094% | 18,995 0.114% |
ROSETTA CAPITAL | ORDINARY | 0 0% | 18,405 0.046% | 18,405 0.091% | 18,405 0.091% | 18,405 0.110% |
EVONNE SEPSIS | ORDINARY | 0 0% | 18,264 0.046% | 18,264 0.090% | 0 0% | 0 0% |
MARK LOWDELL | ORDINARY | 0 0% | 16,961 0.042% | 16,961 0.084% | 16,961 0.084% | 16,961 0.101% |
KATY NEWTON | ORDINARY | 0 0% | 16,000 0.040% | 16,000 0.079% | 16,000 0.079% | 16,000 0.096% |
JURG GEIGY | ORDINARY | 0 0% | 9,188 0.023% | 9,188 0.045% | 9,188 0.045% | 9,188 0.055% |
THOMAS HECHT | ORDINARY | 0 0% | 7,705 0.019% | 7,705 0.038% | 7,705 0.038% | 7,705 0.046% |
NETWORK CAPITAL HOLDING AG | ORDINARY | 0 0% | 6,795 0.017% | 6,795 0.034% | 6,795 0.034% | 6,795 0.041% |
PERNET PORTFOLIO MANAGEMENT | ORDINARY | 0 0% | 5,753 0.014% | 5,753 0.028% | 5,753 0.028% | 5,753 0.034% |
JAKOB SCHLAPBACH | ORDINARY | 0 0% | 4,715 0.012% | 4,715 0.023% | 4,715 0.023% | 4,715 0.028% |
SV LIFE SCIENCES FUND IV, L.P. | ORDINARY | 0 0% | 4,316 0.011% | 4,316 0.021% | 4,316 0.021% | 4,316 0.026% |
MARIANNE OHNEMUS-HUSSER | ORDINARY | 0 0% | 4,054 0.010% | 4,054 0.020% | 4,054 0.020% | 4,054 0.024% |
DOMINICK ESCHER | ORDINARY | 0 0% | 3,690 0.009% | 3,690 0.018% | 3,690 0.018% | 3,690 0.022% |
ADRIAN ESCHER | ORDINARY | 0 0% | 3,007 0.008% | 3,007 0.015% | 3,007 0.015% | 3,007 0.018% |
ALCIDE BARBERIS | ORDINARY | 0 0% | 1,528 0.004% | 1,528 0.008% | 1,528 0.008% | 1,528 0.009% |
JAPAR SHAMSHIEV | ORDINARY | 0 0% | 1,380 0.003% | 1,380 0.007% | 1,380 0.007% | 1,380 0.008% |
JULIA MOLITOR | ORDINARY | 0 0% | 1,380 0.003% | 1,380 0.007% | 1,380 0.007% | 1,380 0.008% |
THOMAS JUNG | ORDINARY | 0 0% | 1,380 0.003% | 1,380 0.007% | 1,380 0.007% | 1,380 0.008% |
HERMANN SCHULZE | ORDINARY | 0 0% | 1,136 0.003% | 1,136 0.006% | 1,136 0.006% | 1,136 0.007% |
ROLAND HARTMANN | ORDINARY | 0 0% | 1,122 0.003% | 1,122 0.006% | 1,122 0.006% | 1,122 0.007% |
LAUREN GILL | ORDINARY | 0 0% | 525 0.001% | 525 0.003% | 525 0.003% | 525 0.003% |
THOMAS LOESER | ORDINARY | 0 0% | 493 0.001% | 493 0.002% | 493 0.002% | 493 0.003% |
GEORGE HAAS | ORDINARY | 0 0% | 467 0.001% | 467 0.002% | 467 0.002% | 467 0.003% |
UNIVERSITY OF ZURICH | ORDINARY | 0 0% | 304 0.001% | 304 0.002% | 304 0.002% | 304 0.002% |
SUSANNE HOHN | ORDINARY | 0 0% | 22 0.000% | 22 0.000% | 22 0.000% | 22 0.000% |
AMEDEO CAFLISCH | ORDINARY | 0 0% | 21 0.000% | 21 0.000% | 21 0.000% | 21 0.000% |
MAYA FURLER | ORDINARY | 0 0% | 1 0.000% | 1 0.000% | 1 0.000% | 1 0.000% |
BAYLOR | BCM PREFERENCE | 0 0% | 0 0% | 451,388 2.23% | 451,388 2.23% | 451,388 2.70% |
ESC ADVISOR | ORDINARY | 0 0% | 0 0% | 0 0% | 18,264 0.090% | 18,264 0.109% |
BIOMEDINVESTILTD | ORDINARY | 0 0% | 0 0% | 0 0% | 0 0% | 43,638 0.261% |
SHAREHOLDINGS (BETA)
no shareholding data
CONTROLLED COMPANIES / CONTROLLING ENTITIES
Controlling entities above
KUUR THERAPEUTICS LIMITED
no controlled companies
LATE PAYMENTS REPORT
This company has not filed any late payment reports possibly because it is not considered \'Large\'.
COURT CASES
No Court Cases found
PATENTS
No Patents found
COMPETITORS
(Based on Sic code:
21200 Manufacture of pharmaceutical preparations)
Company | Registered Address | Company Number | YE Date | Revenue GBP | Net Profit GBP | Other SIC codes |
---|---|---|---|---|---|---|
GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) TRADING LIMITED | BUILDING 5, FIRST FLOOR, THE HEIGHTS, WEYBRIDGE, SURREY, ENGLAND, KT13 0NY | 09237643 | 2017-12-31 | 907,175,000 | 25,390,000 | |
GLAXO OPERATIONS UK LIMITED | 980 GREAT WEST ROAD, BRENTFORD, MIDDLESEX, TW8 9GS | 00711851 | 2017-12-31 | 751,809,000 | 31,941,000 | |
JANSSEN-CILAG LIMITED | 50-100 HOLMERS FARM WAY, HIGH WYCOMBE, BUCKINGHAMSHIRE, HP12 4EG | 01027904 | 2017-12-31 | 552,543,000 | 35,316,000 | |
TEVA UK LIMITED | RIDINGS POINT, WHISTLER DRIVE, CASTLEFORD, ENGLAND, ENGLAND, WF10 5HX | 00302461 | 2017-12-31 | 522,216,000 | 12,568,000 | |
ACCORD HEALTHCARE LIMITED | SAGE HOUSE, 319 PINNER ROAD, NORTH HARROW, MIDDLESEX, HA1 4HF | 04596349 | 2018-03-31 | 466,881,000 | 8,409,000 |
46460-Wholesale of pharmaceutical goods |
CLINIGEN GROUP PLC | PITCAIRN HOUSE CROWN SQUARE, CENTRUM 100, BURTON ON TRENT, STAFFORDSHIRE, DE14 2WW | 06771928 | 2018-06-30 | 381,200,000 | 27,400,000 |
46460-Wholesale of pharmaceutical goods |
NAPP PHARMACEUTICAL HOLDINGS LIMITED | UNIT 196 CAMBRIDGE SCIENCE PARK, MILTON ROAD, CAMBRIDGE, ENGLAND, CB4 0AB | 03486244 | 2017-12-31 | 289,665,000 | 49,250,000 |
46460-Wholesale of pharmaceutical goods |
ACCORD-UK LTD | WHIDDON VALLEY, BARNSTAPLE, DEVON, EX32 8NS | 00079585 | 2018-03-31 | 278,145,000 | 48,706,000 | |
NORBROOK LABORATORIES LIMITED | STATION WORKS, CAMLOUGH ROAD, NEWRY, CO. DOWN, NORTHERN IRELAND, BT35 6JP | NI007665 | 2018-08-03 | 228,695,000 | 34,314,000 | |
NORTON HEALTHCARE LIMITED | RIDINGS POINT, WHISTLER DRIVE, CASTLEFORD, ENGLAND, ENGLAND, WF10 5HX | 00947980 | 2017-12-31 | 178,230,000 | 83,361,000 | |
QUALASEPT LIMITED | 3 CORSHAM SCIENCE PARK, PARK LANE, CORSHAM, WILTSHIRE, UNITED KINGDOM, SN13 9FU | 05548345 | 2018-04-30 | 166,298,470 | 10,410,672 | |
FRESENIUS KABI LIMITED | CESTRIAN COURT, EASTGATE WAY MANOR PARK, RUNCORN, CHESHIRE, WA7 1NT | 02182135 | 2017-12-31 | 121,048,000 | 3,638,000 | |
OMEGA PHARMA LIMITED | WRAFTON, WRAFTON, BRAUNTON, DEVON, ENGLAND, EX33 2DL | 00922235 | 2017-12-31 | 110,053,000 | 8,501,000 |
46460-Wholesale of pharmaceutical goods |
BARD PHARMACEUTICALS LIMITED | UNIT 191, CAMBRIDGE SCIENCE PARK, MILTON ROAD, CAMBRIDGE, ENGLAND, CB4 0GW | 00987562 | 2017-12-31 | 94,324,000 | 24,235,000 | |
FISONS LIMITED | 410 THAMES VALLEY PARK DRIVE, READING, BERKSHIRE, ENGLAND, RG6 1PT | 00044687 | 2016-12-31 | 89,026,000 | -23,024,000 | |
FUJIFILM DIOSYNTH BIOTECHNOLOGIES UK LIMITED | FUJIFILM DIOSYNTH BIOTECHNOLOGIES, BELASIS AVENUE, BILLINGHAM, TS23 1LH | 05803359 | 2018-03-31 | 81,400,000 | 13,500,000 |
72110-Research and experimental development on biotechnology |
QUANTUM PHARMACEUTICAL LIMITED | QUANTUM HOUSE, HOBSON INDUSTRIAL ESTATE, BURNOPFIELD, CO DURHAM, NE16 6EA | 05240304 | 2018-06-30 | 76,092,000 | -8,345,000 | |
ALMAC PHARMA SERVICES LIMITED | ALMAC HOUSE, 20 SEAGOE INDUSTRIAL ESTATE, CRAIGAVON, BT63 5QD | NI045055 | 2017-09-30 | 69,660,684 | 4,207,021 | |
MORNINGSIDE PHARMACEUTICALS LIMITED | NENE HOUSE, 4 RUSHMILLS, NORTHAMPTON, ENGLAND, NN4 7YB | 02672877 | 2017-12-31 | 62,737,482 | 6,004,935 |
32500-Manufacture of medical and dental instruments and supplies 46460-Wholesale of pharmaceutical goods |
CALEA UK LIMITED | CESTRIAN COURT, EASTGATE WAY MANOR PARK, RUNCORN, CHESHIRE, WA7 1NT | 02506615 | 2017-12-31 | 62,638,000 | 7,746,000 | |
CATALENT CTS (EDINBURGH) LIMITED | . FRANKLAND ROAD, BLAGROVE, SWINDON, WILTSHIRE, ENGLAND, SN5 8YG | 05277708 | 2018-06-30 | 54,067,315 | 16,583,236 | |
DERMAL LABORATORIES LIMITED | HASLERS, OLD STATION ROAD, LOUGHTON, ESSEX, IG10 4PL | 01594795 | 2017-05-31 | 43,052,720 | 0 | |
DERMAL LABORATORIES LIMITED | HASLERS, OLD STATION ROAD, LOUGHTON, ESSEX, IG10 4PL | 01594795 | 2018-05-31 | 41,451,144 | 2,331,327 | |
DR REDDY'S LABORATORIES (UK) LIMITED | 410 CAMBRIDGE SCIENCE PARK, MILTON ROAD, CAMBRIDGE, ENGLAND, CB4 0PE | 01729064 | 2018-03-31 | 40,429,896 | 0 | |
NAPP PHARMACEUTICAL GROUP LIMITED | UNIT 196 CAMBRIDGE SCIENCE PARK, MILTON ROAD, CAMBRIDGE, ENGLAND, CB4 0AB | 00884285 | 2017-12-31 | 38,211,000 | 17,231,000 |
46460-Wholesale of pharmaceutical goods |
FOCUS PHARMACEUTICALS LIMITED | DASHWOOD HOUSE, 69 OLD BROAD STREET, LONDON, UNITED KINGDOM, EC2M 1QS | 04522142 | 2017-12-31 | 37,170,564 | 10,869,254 |
46460-Wholesale of pharmaceutical goods 72190-Other research and experimental development on natural sciences and engineering |
NICOBRAND LIMITED | 189 CASTLEROE ROAD, COLERAINE, COUNTY LONDONDERRY, NORTHERN IRELAND, NORTHERN IRELAND, BT51 3RP | NI033276 | 2017-12-31 | 11,981,230 | 0 | |
AURALIS LIMITED | 1 KINGDOM STREET, LONDON, ENGLAND, W2 6BD | 05335695 | 2017-12-31 | 1,473,000 | 1,251,000 | |
EMERGENCYPHARM LTD. | 69 ROUNDHILL AVENUE, BINGLEY, ENGLAND, BD16 1PQ | 09263308 | 2018-10-31 | 47,990 | 0 | |
AFZAL PHARMA LTD | 156 NORMAN PLACE ROAD, COVENTRY, ENGLAND, CV6 2BU | 09090499 | 2018-06-30 | 30,127 | 0 | |
ARCADIA PHARMA LIMITED | UNIT 3 FELINFACH, FFORESTFACH, SWANSEA, SA5 4HP | 08497840 | 2018-12-31 | 0 | 0 | |
BESCOT HEALTHCARE UK LIMITED | 272 BATH STREET, GLASGOW, G2 4JR | SC474960 | 2019-04-30 | 0 | 0 | |
HYPERION CATALYSIS EU LIMITED | 4385, 06729299 - COMPANIES HOUSE DEFAULT ADDRESS, CARDIFF, CF14 8LH | 06729299 | 2018-03-31 | 0 | 0 |
32990-Other manufacturing not elsewhere classified 72190-Other research and experimental development on natural sciences and engineering |
FOCUS PHARMA HOLDINGS LIMITED | CAPITAL HOUSE, 85 KING WILLIAM STREET, LONDON, EC4N 7BL | 06317129 | 0000-00-00 | 0 | 0 |
46460-Wholesale of pharmaceutical goods 72190-Other research and experimental development on natural sciences and engineering |
QUALASEPT HOLDINGS LIMITED | 3 CORSHAM SCIENCE PARK, PARK LANE, CORSHAM, WILTSHIRE, UNITED KINGDOM, SN13 9FU | 10135621 | 0000-00-00 | 0 | 0 | |
QUANTUM PHARMA 2014 LIMITED | 25 BEDFORD SQUARE, BLOOMSBURY, LONDON, UNITED KINGDOM, WC1B 3HH | 09269809 | 0000-00-00 | 0 | 0 |
70100-Activities of head offices |
QUANTUM PHARMA HOLDINGS LIMITED | 25 BEDFORD SQUARE, BLOOMSBURY, LONDON, UNITED KINGDOM, WC1B 3HH | 09269818 | 0000-00-00 | 0 | 0 | |
REMEDI MEDICAL HOLDINGS LIMITED | NENE HOUSE, 4 RUSHMILLS, NORTHAMPTON, ENGLAND, NN4 7YB | 08735617 | 0000-00-00 | 0 | 0 |
46460-Wholesale of pharmaceutical goods |
LIQUIDATION RISK (BETA)
This company is Liquidation. Statistically, such companies have a VERY HIGH probability of being liquidated within a year.
Here are our probability predictions:
Basis | Liquidation within 3 months | Liquidation within 6 months | Liquidation within 12 months | Prediction confidence |
---|---|---|---|---|
Company status | 100.0% | 99.4% | 99.9% | High |
Other companies Active in the same sector | Too few competitors | |||
Age | 0.4% | 1.7% | 3.3% | Medium |
Company Type | 0.7% | 3.7% | 7.4% | Medium |
Accounts category | 0.6% | 1.5% | 2.5% | Medium |
Accounting Month | 0.6% | 2.4% | 5.5% | Medium |
Sic code count | 0.8% | 4.4% | 8.7% | Medium |